The New Zealand Herald10d
Daratumumab: Rotorua cancer survivor Tove Jensen-Munroe calls for drug funding
Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.
The New Zealand Herald11d
Cancer survivor calls for funding of Daratumumab
The French river cruise prize package is sold for $29,000 to top bidder Dennis Walsh and Cathie Waites at Rotorua's Supper Club charity fundraiser. The Hits Rotorua 97.5FM presenter Paul Hickey ...
National Institute for Health and Care Excellence10d
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249
Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...
Morningstar1mon
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Morningstar brands and products Company Portfolio ...